Table 6.
Route/type/adequacy scoring | Number of (sub-)studies | Positive* | Negative* | Labs† |
---|---|---|---|---|
Inhalation | ||||
Total | 0 | 0 | 0 | 0 |
Oral | ||||
Total | 20 | 15 | 5 | 11 |
High score | 7 | 4 | 3 | 4 |
Low score | 13 | 11 | 2 | 7 |
Dermal | ||||
Total | 1 | 1 | 0 | 1 |
High score | 0 | 0 | 0 | 0 |
Low score | 1 | 1 | 0 | 1 |
Other | ||||
Total | 14 | 8 | 6 | 11 |
High score | 4 | 2 | 2 | 3 |
Low score | 10 | 6 | 4 | 8 |
Note: To facilitate comparisons, the (sub-)studies were grouped into high and low-adequacy scoring studies with overall scores subjectively set to >2 and ≤2, respectively.
*As judged by the authors of the respective studies, where “positive” indicates stimulating carcinogenesis and “negative” indicates a lack of carcinogenic effect.
†Number of different laboratories contributing studies.